Aminophylline tablets pass generic drug consistency evaluation
January 30, 2026
Source: https://finance.eastmoney.com/a/202601293635246476.html
30
On January 29, Lisheng Pharmaceutical(002393) issued an announcement stating that recently, the company received a "Drug Supplement Application Approval Notice" from the National Medical Products Administration regarding the 0.1g specification of aminophylline tablets, with approval number 2026B00421. This drug has passed the consistency evaluation of generic drug quality and efficacy. The drug's indications include bronchial asthma, wheezing bronchitis, and obstructive emphysema.
Passing the consistency evaluation will help enhance the drug's market competitiveness. However, due to the nature of the pharmaceutical industry, the specific sales performance of various products may be affected by factors such as changes in the market environment, and therefore has considerable uncertainty.
In the first three quarters of 2025, Lisheng Pharmaceutical achieved revenue of RMB 1.007 billion and net profit attributable to the parent company of RMB 371 million.
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Initial Clinical Exploration of D-0502 in Combination with ADC Therapies Officially Commenced. January 30, 2026
- Pfizer’s blockbuster drug receives notice of approval! January 30, 2026
- Propafenone Hydrochloride Injection Receives Drug Production Registration Certificate January 30, 2026
- Hengrui’s innovative drug camrelizumab in combination with apatinib mesylate and TACE for the treatment of liver cancer has been accepted for marketing authorization application January 30, 2026
- The world’s first clinically approved “autologous regenerated islets” for the treatment of type 2 diabetes! Ruipuchen Chuang opens a new dual-indication autologous regeneration track. January 30, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
